Precision epigenetic therapy for B-cell lymphoma
Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus,…
Date: 18th July 2019
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…
Date: 18th July 2019
Precision epigenetic therapy for B-cell lymphoma
Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus,…
Date: 18th July 2019
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…
Date: 18th July 2019
iwAL 2019: looking to the future of acute leukemia therapy
The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods…
Date: 6th June 2019
Acute leukemia: pushing boundaries in disease management
This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology…
Date: 6th June 2019
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges….
Date: 18th December 2018
MRD testing in multiple myeloma: new technology with promising clinical applications
Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…
Date: 23rd November 2018
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…
Date: 11th October 2018
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL)…
Date: 14th September 2018
CLL therapies today: novel agents, combinations & the future of the field
Chronic lymphocytic leukemia (CLL) is experiencing a revolution in its treatment approaches. New therapies are constantly in development, and the…
Date: 20th August 2018
CAR T-cell therapy: where are we now and what’s in store for the future?
Over the last several years, CAR T-cell therapy has emerged as a revolution in immunotherapy, with incredible results to date….
Date: 25th July 2018
Focus on MRD: current landscape and future questions in hemonc
Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting….
Date: 4th July 2018
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…
Date: 16th March 2018
Acute leukemias: is MRD already a surrogate for survival?
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…
Date: 9th March 2018
Revolutionary immunotherapies for lymphoma
Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new…
Date: 2nd February 2018
Latest advances and current challenges in immunotherapies for lymphoma
In this lively discussion, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System and George Washington University,…
Date: 15th December 2017
The circle of CLL: from gene discovery to targeted treatment
In this exciting feature, Carlo Croce, MD, from Ohio State University, Columbus, OH, provides an overview of the history of…
Date: 8th December 2017
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Date: 16th November 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
Date: 16th November 2017
Debate on the use of MRD for multiple myeloma management
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Date: 16th November 2017
